We would like to present the case of a patient who had a prior history of cannabis, ecstasy (MDM A) and LSD abuse and who developed both Hallucinogen Persisting Perception Disorder (HPPD) and a major depressive episode. Following two unsuccessful SSRIs trials, reboxetine was prescribed. During a six-month follow-up period on reboxetine 6 mg./day, no exacerbation of the visual disturbance or recurrence of the depressive features were reported. Reboxetine may have an α2 adrenoreceptor modulating effect on both noradrenaline and serotonin release, thus reboxetine's α2 adrenoreceptor modulating effect on noradrenaline release may affect sympathetic activity and be involved in the recovery process.
|Number of pages||4|
|Journal||Israel Journal of Psychiatry and Related Sciences|
|State||Published - 2002|
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health